Mesenchymal stromal cells
Phase 2Biologic
Mario Negri Institute for Pharmacological ResearchMesenchymal stromal cells is one of 294 biologic programs targeting Liver Transplant. It is currently in Phase 2.
12
Indications
26
Total Trials
6
Active Trials
293
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Mesenchymal stromal cells
Mario Negri Institute for Pharmacological ResearchPhase 2
Spikevax
ModernaPreclinical
Bnt162b2
BioNTechPreclinical
COVID-19 Vaccine
ModernaPreclinical
Biaxin
AbbViePreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Singulair
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-194 trials
Acute Respiratory Distress Syndrome2 trials
Kidney Transplant2 trials
Chronic Graft Versus Host Disease2 trials
15 more indications
Conditioning1 trial
Renal Transplant Recipients1 trial
Diabetic Foot1 trial
Recessive Dystrophic Epidermolysis Bullosa1 trial
Acute Respiratory Failure1 trial
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
Completed·—·Phase 1/2·NCT04345601·28 enrolled
Systemic Sclerosis1 trial
Allogeneic Hematopoietic Stem Cell Transplantation1 trial
Brain Injury1 trial
Acute Graft Versus Host Disease1 trial
Complication1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mesenchymal stromal cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details